Роберто Пили
About
Роберто Пили is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology.
According to data from OpenAlex, Роберто Пили has authored 289 papers receiving a total of 13.0k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Molecular Biology, 140 papers in Pulmonary and Respiratory Medicine and 84 papers in Oncology. Recurrent topics in Роберто Пили's work include Renal cell carcinoma treatment (69 papers), Prostate Cancer Treatment and Research (63 papers) and Histone Deacetylase Inhibitors Research (53 papers). Роберто Пили is often cited by papers focused on Renal cell carcinoma treatment (69 papers), Prostate Cancer Treatment and Research (63 papers) and Histone Deacetylase Inhibitors Research (53 papers). Роберто Пили collaborates with scholars based in United States, Italy and Canada. Роберто Пили's co-authors include Michael A. Carducci, David Z. Qian, Hans J. Hammers, Antonino Passaniti, Leigh Ellis, Li Shen, Henk M.W. Verheul, Peter Atadja, George Wilding and Robert J. Motzer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Circulation.
In The Last Decade
Роберто Пили
280 papers receiving 12.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Роберто Пили United States | 59 | 7.8k | 4.2k | 3.8k | 3.0k | 1.3k | 289 | 13.0k | ||
| Robert S. DiPaola United States | 49 | 5.9k 0.8× | 5.4k 1.3× | 3.1k 0.8× | 3.2k 1.1× | 1.1k 0.8× | 234 | 14.2k | ||
| Phillip A. Dennis United States | 49 | 7.6k 1.0× | 2.5k 0.6× | 4.6k 1.2× | 2.2k 0.7× | 1.2k 0.9× | 137 | 12.4k | ||
| Michèle Milella Italy | 54 | 5.6k 0.7× | 2.5k 0.6× | 6.5k 1.7× | 2.5k 0.8× | 1.5k 1.2× | 370 | 12.9k | ||
| Michael I. Koukourakis Greece | 60 | 6.1k 0.8× | 2.6k 0.6× | 3.9k 1.1× | 5.0k 1.7× | 1.1k 0.8× | 332 | 13.0k | ||
| Eric B. Haura United States | 63 | 8.8k 1.1× | 3.7k 0.9× | 7.0k 1.9× | 2.8k 0.9× | 1.9k 1.5× | 278 | 14.7k | ||
| Stefan Sleijfer Netherlands | 61 | 4.2k 0.5× | 4.7k 1.1× | 7.1k 1.9× | 3.5k 1.2× | 1.5k 1.1× | 379 | 13.6k | ||
| W. Kimryn Rathmell United States | 52 | 6.6k 0.9× | 4.6k 1.1× | 2.4k 0.6× | 3.9k 1.3× | 1.1k 0.8× | 232 | 10.3k | ||
| Siqing Fu United States | 51 | 3.8k 0.5× | 2.4k 0.6× | 4.1k 1.1× | 2.4k 0.8× | 954 0.7× | 412 | 9.6k | ||
| Kazuaki Takabe United States | 60 | 7.0k 0.9× | 2.3k 0.5× | 4.3k 1.2× | 2.8k 0.9× | 2.1k 1.6× | 398 | 12.6k | ||
| John Wagstaff United Kingdom | 46 | 4.5k 0.6× | 3.5k 0.8× | 4.4k 1.2× | 2.0k 0.7× | 2.1k 1.6× | 206 | 10.5k |
Countries citing papers authored by Роберто Пили
Since
Specialization
Citations
This map shows the geographic impact of Роберто Пили's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Роберто Пили with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Роберто Пили more than expected).
Fields of papers citing papers by Роберто Пили
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Роберто Пили. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Роберто Пили. The network helps show where Роберто Пили may publish in the future.
Co-authorship network of co-authors of Роберто Пили
This figure shows the co-authorship network connecting the top 25 collaborators of Роберто Пили. A scholar is included among the top collaborators of Роберто Пили based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Роберто Пили. Роберто Пили is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Epstein, Joel B., et al.. (2024). The integration of big data analytics in examining the effects of mental illness screening on mortality and burden of illness among patients with cancer.. Journal of Clinical Oncology. 42(16_suppl). e23083–e23083.
2.
Fang, Shuyi, Sheng Liu, Xufeng Chen, et al.. (2020). Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer. Cancer Research. 80(22). 4904–4917.
3.
Affronti, Hayley C., Aryn M. Rowsam, Spencer R. Rosario, et al.. (2020). Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy. Nature Communications. 11(1). 52–52.
4.
Elbanna, May, Ashley Orillion, Nur P. Damayanti, et al.. (2019). Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma. Molecular Cancer Therapeutics. 19(1). 147–156.
5.
Fishel, Melissa L., May Elbanna, Hristos Z. Kaimakliotis, et al.. (2019). Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer. Molecular Cancer Therapeutics. 18(11). 1947–1960.
6.
Adelaiye‐Ogala, Remi, Nur P. Damayanti, Ashley Orillion, et al.. (2018). Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma. Cancer Research. 78(11). 2886–2896.
7.
Orillion, Ashley, Nur P. Damayanti, Li Shen, et al.. (2018). Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy. Clinical Cancer Research. 24(24). 6383–6395.
8.
Damayanti, Nur P., Justin A. Budka, Heba Khella, et al.. (2018). Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. Clinical Cancer Research. 24(23). 5977–5989.
9.
Thompson, John A., Robert J. Motzer, Ana M. Molina, et al.. (2018). Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. Clinical Cancer Research. 24(18). 4399–4406.
10.
Orillion, Ashley, Ayumi Hashimoto, Nur P. Damayanti, et al.. (2017). Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clinical Cancer Research. 23(17). 5187–5201.
11.
Пили, Роберто, David I. Quinn, Hans J. Hammers, et al.. (2017). Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870). Clinical Cancer Research. 23(23). 7199–7208.
12.
Montgomery, Bruce, Mario A. Eisenberger, Matthew B. Rettig, et al.. (2015). Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer. Clinical Cancer Research. 22(6). 1356–1363.
13.
Adelaiye‐Ogala, Remi, Eric Ciamporcero, Kiersten Marie Miles, et al.. (2014). Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications. Molecular Cancer Therapeutics. 14(2). 513–522.
14.
Shen, Li, Anette Sundstedt, Michael J. Ciesielski, et al.. (2014). Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models. Cancer Immunology Research. 3(2). 136–148.
15.
Armstrong, Andrew J., Michael Häggman, Walter M. Stadler, et al.. (2013). Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 19(24). 6891–6901.
16.
Ebos, John M.L. & Роберто Пили. (2012). Mind the Gap: Potential for Rebounds during Antiangiogenic Treatment Breaks. Clinical Cancer Research. 18(14). 3719–3721.
17.
Gotink, Kristy J., Henk J. Broxterman, Mariëtte Labots, et al.. (2011). Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance. Clinical Cancer Research. 17(23). 7337–7346.
18.
Пили, Роберто, Michael Häggman, Walter M. Stadler, et al.. (2011). Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer. Journal of Clinical Oncology. 29(30). 4022–4028.
19.
Motzer, Robert J., Thomas E. Hutson, Piotr Tomczak, et al.. (2009). Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 27(22). 3584–3590.
20.
Carducci, Michael A., Luna Musib, Merrill S. Kies, et al.. (2006). Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer. Journal of Clinical Oncology. 24(25). 4092–4099.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Robert S. DiPaola Breakdown of academic impact, for papers by Phillip A. Dennis Breakdown of academic impact, for papers by Michèle Milella Breakdown of academic impact, for papers by Michael I. Koukourakis Breakdown of academic impact, for papers by Eric B. Haura Breakdown of academic impact, for papers by Stefan Sleijfer Breakdown of academic impact, for papers by W. Kimryn Rathmell Breakdown of academic impact, for papers by Siqing Fu Breakdown of academic impact, for papers by Kazuaki Takabe Breakdown of academic impact, for papers by John Wagstaff